Pilgrim Raises $25M for ARGUS Biothreat Detection

By the time an airborne biological sample reaches a centralized lab, the environment it represents may already have changed. Pilgrim is financing an attempt to move the first layer of biological detection closer to the air itself, where an hour can matter more than another week of analysis.

The Redwood City defense-biotechnology company raised a $25M Seed round led by Buckley Ventures at a reported $150M valuation. Wall Street Journal reporting published September 23, 2026 also identified Anthropic employees Logan Graham and Sholto Douglas as personal investors, connecting the frontier-AI risk conversation to a physical layer of biosecurity.

Pilgrim's central product is ARGUS, a 50-pound autonomous biosurveillance system designed to collect airborne biological material, screen for known and novel threats, and analyze results on-device. Pilgrim publishes a time to result under 60 minutes, a collection rate of 325 liters per minute, and UV LIF, qPCR, and sequencing detection modes.

What Pilgrim Raised

The $25M financing follows a $4.3M Seed round reported in 2025. Business Insider identified Cantos as the lead in that earlier round, with Thiel Capital, Day One Ventures, Refactor Capital, Joshua Browder, Cory Levy, and Adrian Fenty among the participants. Axios subsequently described Pilgrim as a defense-biotechnology company building battlefield medical and surveillance products.

Buckley Ventures led the new round. Pilgrim's current investor page also lists Thiel Capital, Cantos, Conviction, Shine Capital, Mantis, Refactor Capital, and Magellan, but the public list should not be mistaken for a complete roster of participants in this specific financing. The reviewed reporting does not establish whether the $150M valuation is pre-money or post-money, and Pilgrim has not published an audited lifetime-funding history.

The new capital materially expands Pilgrim's room to manufacture, deploy, and validate hardware, although the company has not published a detailed use-of-funds breakdown. At a reported $150M Seed valuation, the operating obligation is larger than the device: Pilgrim has to demonstrate that early warning can function as dependable infrastructure inside institutions that do not get to treat a bad alert like a software bug.

ARGUS Moves Biosurveillance Closer to the Air

Traditional biosurveillance often depends on collection, transport, and testing in centralized laboratories. That model can be rigorous, but it creates a physical delay between what is in the environment and what an institution knows. It can also focus testing on a predefined list of threats when the first operational question is broader: what is present, and does anyone need to respond?

Pilgrim says ARGUS combines collection, screening, and analysis in one portable system. Its published specifications list a footprint of 17 by 21 by 26 inches, edge computing rated at 157 TOPS, and intended applications across defense, homeland security, and public health. Those are first-party specifications, not independent proof of sensitivity, specificity, field reliability, or false-positive performance.

That qualification does not make the system unimportant. It defines the work ahead. A useful biological-threat detector must operate in messy air, distinguish meaningful signals from environmental noise, protect genomic data, connect to confirmatory testing, and fit the response protocols of the agency, hospital, airport, base, port, or farm using it.

The Team Is Building for Institutional Deployment

Jake Adler is Pilgrim's founder and CEO. The company's official leadership page lists Fernando Soto as Head of Science, Mauricio Moel as Head of Operations, and Todd Ritter as Head of Government. Pilgrim does not currently publish a CTO on that page, so one should not be inferred from the company's technical scope.

The leadership mix is consistent with the job Pilgrim has chosen. Science has to identify the threat, hardware has to survive the field, operations has to manufacture and deploy the system, and government work has to translate national priorities into programs that can actually buy and use it. A biosecurity device can be technically impressive and still fail at any one of those handoffs.

Pilgrim's updates page says the company opened a 20,000-square-foot facility in Redwood City and signed an agreement with the CDC for biosurveillance. Adler has also said Pilgrim has multiple federal deployments during 2026. The public record reviewed for this article does not provide the CDC agreement's value, term, deployment scope, or independent performance results, so those claims remain company-reported operating signals rather than audited traction.

Why This Round Matters

Pilgrim sits inside two markets that increasingly overlap. One is the modernization of defense and national-security hardware. The other is the growing concern that advanced biological tools, including AI-assisted research, can compress the time and expertise required to create or modify dangerous agents. Graham and Douglas investing personally does not make Anthropic a corporate backer, but it does show that people working near frontier-AI risk see physical detection as part of a defense-in-depth strategy.

The commercial opportunity extends beyond a single government program. Airports, hospitals, ports, farms, laboratories, military bases, and other critical sites all have reasons to care about earlier environmental warning. Yet the buying path is difficult because the customer is not purchasing a sensor alone. It is purchasing a reliable sequence of detection, confirmation, authority, communication, and response.

That sequence is also Pilgrim's competitive test. A machine that reports a possible pathogen in under 60 minutes could change how institutions manage biological risk, but only if the signal earns trust and the surrounding organization knows what to do next. False positives can trigger costly responses, missed detections can create false confidence, and unclear ownership can waste the time the system was built to save.

What Pilgrim Must Prove Next

The $25M round gives Pilgrim resources to move ARGUS from promising hardware toward deployed infrastructure. The next evidence should be concrete: independently validated performance, reliability in complex environments, secure data handling, manufacturing repeatability, procurement progress, and a clear connection between an alert and the institution responsible for acting on it.

Pilgrim's ambition is to build an American biology prime, a company capable of carrying biotechnology from research through manufacturing and field deployment. The financing makes that ambition more plausible, but the stronger signal will come from the response chain that forms around ARGUS when the air contains something an institution cannot afford to misunderstand.